MX2021010453A - Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. - Google Patents
Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.Info
- Publication number
- MX2021010453A MX2021010453A MX2021010453A MX2021010453A MX2021010453A MX 2021010453 A MX2021010453 A MX 2021010453A MX 2021010453 A MX2021010453 A MX 2021010453A MX 2021010453 A MX2021010453 A MX 2021010453A MX 2021010453 A MX2021010453 A MX 2021010453A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- adcs
- drug conjugates
- dlk1
- against human
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 8
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 4
- 101150102995 dlk-1 gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 101000928535 Homo sapiens Protein delta homolog 1 Proteins 0.000 abstract 2
- 102100036467 Protein delta homolog 1 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con nuevos conjugados anticuerpo-fármaco (ADC) dirigidos a DLK1, metabolitos activos de tales ADC, métodos para la preparación de tales ADC, usos para tales ADC en el tratamiento y/o la prevención de enfermedades, y usos de tales ADC en la producción de fármacos para el tratamiento y/ o la prevención de enfermedades, más específicamente, usos de tales ADC en la producción de fármacos para el tratamiento y/o la prevención de enfermedades proliferativas y/o angiogenéticas, por ejemplo, cáncer. Más particularmente, la presente invención se relaciona con un conjugado anticuerpo-fármaco que comprende un anticuerpo que se une a DLK1 o un fragmento de unión a antígeno de este, y una composición farmacéutica que comprende este.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190025987 | 2019-03-06 | ||
KR1020200027373A KR102503143B1 (ko) | 2019-03-06 | 2020-03-04 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
PCT/KR2020/003100 WO2020180121A1 (ko) | 2019-03-06 | 2020-03-05 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010453A true MX2021010453A (es) | 2021-09-21 |
Family
ID=72337989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010453A MX2021010453A (es) | 2019-03-06 | 2020-03-05 | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220339291A1 (es) |
EP (1) | EP3936150A4 (es) |
JP (1) | JP2022522547A (es) |
BR (1) | BR112021017303A2 (es) |
MX (1) | MX2021010453A (es) |
WO (1) | WO2020180121A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101628872B1 (ko) * | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
EP3380125A4 (en) | 2015-11-25 | 2019-08-28 | LegoChem Biosciences, Inc. | CONJUGATES WITH PEPTIDE GROUPS AND RELATED METHODS |
WO2017089895A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
CN117244076A (zh) | 2015-11-25 | 2023-12-19 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
KR101938800B1 (ko) | 2017-03-29 | 2019-04-10 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
CA3099680A1 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
JPH02500876A (ja) | 1987-03-20 | 1990-03-29 | クリエイティブ・バイオマリキュールズ・インコーポレーテッド | 組換えポリペプチドの製品およびその製造、単離および精製方法 |
WO1988007086A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
CA2669731C (en) * | 2006-11-10 | 2016-01-19 | Livtech Inc. | Anti-human dlk-1 antibody showing anti-tumor activity in vivo |
US8017118B2 (en) * | 2008-03-17 | 2011-09-13 | LivTech Inc. — Teikyo University Biotechnology Research Center | Anti-hDlk-1 antibody having an antitumor activity in vivo |
KR101461706B1 (ko) * | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
WO2012138102A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
CA2835576C (en) | 2011-05-08 | 2021-01-05 | Legochem Biosciences, Inc. | Protein-active agent conjugates and method for preparing the same |
KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
WO2017089895A1 (en) * | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018146199A1 (en) * | 2017-02-08 | 2018-08-16 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
KR101966672B1 (ko) | 2017-03-22 | 2019-04-09 | 신화인터텍 주식회사 | 파장 변환 부재 및 이를 포함하는 디스플레이 장치 |
WO2018182341A1 (ko) * | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
KR101938800B1 (ko) | 2017-03-29 | 2019-04-10 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
KR102286050B1 (ko) | 2017-06-23 | 2021-08-03 | 현대자동차주식회사 | 차량 네트워크에서 진단 오류 방지를 위한 방법 및 장치 |
KR20190018400A (ko) * | 2017-08-14 | 2019-02-22 | 주식회사 레고켐 바이오사이언스 | EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체 |
WO2019050362A2 (ko) * | 2017-09-08 | 2019-03-14 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
KR20200084802A (ko) * | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
-
2020
- 2020-03-05 EP EP20765639.8A patent/EP3936150A4/en active Pending
- 2020-03-05 BR BR112021017303A patent/BR112021017303A2/pt unknown
- 2020-03-05 MX MX2021010453A patent/MX2021010453A/es unknown
- 2020-03-05 JP JP2020541718A patent/JP2022522547A/ja active Pending
- 2020-03-05 US US16/964,965 patent/US20220339291A1/en active Pending
- 2020-03-05 WO PCT/KR2020/003100 patent/WO2020180121A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2022522547A (ja) | 2022-04-20 |
BR112021017303A2 (pt) | 2021-11-16 |
US20220339291A1 (en) | 2022-10-27 |
EP3936150A4 (en) | 2023-03-29 |
EP3936150A1 (en) | 2022-01-12 |
WO2020180121A1 (ko) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010453A (es) | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. | |
MX2022002592A (es) | Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo. | |
PH12019502545A1 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
MX2020013832A (es) | Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado. | |
MX2021014960A (es) | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
WO2021239935A9 (en) | Neutralizing antibodies against sars-related coronavirus | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
MX2023011507A (es) | Conjugado anticuerpo- farmaco que incluye un anticuerpo contra la cldn18.2 humana y uso del mismo. | |
BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
AU2020380603A8 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
WO2020132658A3 (en) | Tubulysins and protein-tubulysin conjugates | |
SG11201910113PA (en) | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
MX2023002940A (es) | Moleculas de union a b7-h4 terapeuticas. | |
CL2023000099A1 (es) | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular | |
MX2022002555A (es) | Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres. | |
MX2021014553A (es) | Terapia de combinacion. |